Pioglitazone insulin sensitivity and type 2 diabetes mellitus: Recent data;Pioglitazone, insulinosensibilité et diabète de type 2: Données récentes

Annales d'Endocrinologie

Volumn 65, Issue 2, 2004, Pages 136-148

  Monnier, L ^a   Sauvanet, J P ^b  

^a LAPEYRONIE HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Cardiovascular morbi mortality; Cardiovascular prevention; Pioglitazone; Type 2 diabetes mellitus; pancreatic cell

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLICLAZIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; CARDIOVASCULAR SYSTEM; DRUG INDICATION; FEMALE; FRANCE; HIGH RISK POPULATION; HUMAN; INSULIN SENSITIVITY; MALE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL TRIAL; DIABETES CONTROL; DRUG EFFECT; DRUG MECHANISM; EDEMA; HYPOGLYCEMIA; INSULIN RELEASE; LIPID BLOOD LEVEL; PREVENTIVE MEDICINE; SIDE EFFECT;

EID: 3042622123     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4266(04)95662-4     Document Type: Article

References (81)

1. Ricordeau P, Weill A, Vallier N, Bourrel R, Fender P, Allemand H. L'épidémiologie du diabète en France métropolitaine. Diabetes Metab 2000; 26: 11-24.
2. Ricordeau P, Weill A, Vallier N et al. The prevalence and cost of diabetes in metropolitan France: what trends between 1998 and 2000? Diabetes Metab 2003, 29: 497-504.
3. Ricordeau P, Weill A, Vallier N, Bourrel R, Fender P, Allemand H. Le coût du diabète en France métropolitaine. Diabetes Metab 2000; 26: 25-38.
4. AFSSAPS. Traitement médicamenteux du diabète de type 2. Recommandations: texte long, argumentaire. Diabetes Metab 1999; 25 (6): 1-79.
5. Stratégie de prise en charge du patient diabétique de type 2 à l'exclusion de la prise en charge des complications. Recommandations de l'ANAES. Mars 2000. Diabetes Metab 2000, 26 (Suppl. 5): 1-96.
6. Sakamoto J, Kimura H, Moriyama S et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000, 278: 704-711.
7. Spiegelman BM. PPAR-γ. adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47: 507-514.
8. Mukherjee R, Davies P, Crombie D et al. Sensitization of diabetic and obese mice to insulin by RXR agonists. Nature 1997, 386: 407-410.
9. Girard J. Mécanisme d'action des thiazotidinediones. Diabetes Metab 2001, 27: 271-278.
10. Martin G, Schoonjans K, Staels B, Auwerx J. PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 1999, 137 (Suppl.): S75-S80.
11. Reginato MJ, Lazar MA. Mechanisms by which thiazolidinediones enhance insulin action. Trends Endocrinol Metab 1999, 10: 9-13.
12. Olefsky JM, Saltiel AR. PPARγ and the treatment of insulin resistance. Trends Endocrinol Metab 2000, 11: 362-368.
13. Stears AJ, Byrne CD. Adipocyte metabolism and the metabolic syndrome. Diabetes Obes Metab 2001, 3: 129-142.
14. Bajaj M, Suraamornkul S, Pratipanawatr T et al. Pioglitazone reduces hepatic fat content and ugments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003, 52: 1364-1370.
15. Girard J. PPARγ et insulino-résistance. Ann Endocrinol 2002, 63:1S19-1S22.
16. Combs TP, Wagner JA, Berger J et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002, 143: 998-1007.
17. Yu JG, Javorschi S; Hevener AL et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetics. Diabetes 2002, 51: 2968-2974.
18. Phillips SA, Ciaraldi TP, Kong APS et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003, 52: 667-674.
19. Iwaki M, Matsuda M, Maeda N et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003, 52: 1655-1663.
20. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat hormone? Diabetes Care 2003, 26: 2442-2450.
21. Smith S, Janderova L, Volaufova J, Bray G. Pioglitazone increases adipose tissue adiponectin mRNA and plasma adiponectin. Diabetes 2003, 52 (Suppl.1): A133 [Abstract 573-P].
22. Bajaj M, Suraamornkul S, Piper P et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004, 89: 200-206.
23. Pavo I, Herz M, Tan M et al., for the Pioglitazone GLAE Study Group. Pioglitazone enhances insulin sensitivity in patients with type 2 diabetes mellitus. Diabetologia 2002, 45 (Suppl.2): A250 [Abstract 779].
24. Johns D, Strand J, Halse J et al., and the GLAC Study Group. The long-term effects of pioglitazone and glibenclamide on glycemic control and insulin sensitivity in patients with type 2 diabetes. Diabetologia 2003, 46 (Suppl.2): A287 [Abstract PS829].
25. Tan M, Herz M, Johns D et al., and the GLAD Study Group. Long-term effects of pioglitazone and glimépiride on insulin sensitivity and glycemic control in patients with type 2 diabetes. Diabetes Metab 2003, 29 (Hors série 2): 4S252 [Abstract 2297].
26. Rosenstock J, for the Pioglitazone HCL Study Group. Improved insulin sensitivity and beta-cell responsitivity suggested by HOMA analysis of pioglitazone therapy. Diabetologia 2000, 43 (Suppl. 1): A192 [Abstract 738].
27. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE and the Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001, 12: 413-423.
28. Miyazaki Y, Matsuda M, DeFronzo M. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002, 25: 517-523.
29. Miyazaki Y, Mahankali A, Matsuda M et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001, 24: 710-719.
30. Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000, 60: 333-343.
31. Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 2001, 23: 1792-1823.
32. Blickle JF. Thiazolidinediones: données cliniques et perspectives. Diabetes Metab 2001, 27: 279-285.
33. Brunetti P. Pioglitazone - current profile. Br J Diabetes Vasc Dis 2002, 2 (Suppl.1): S18-S23.
34. Aronoff S, Rosenblatt S, Braithwaite S et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. A 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000, 23: 1605-1611.
35. Egan JW, Mathisen AL, pioglitazone 012 study Group. The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes. Diabetes 2000, 49 (Suppl.1): A105 [Abstract 423].
36. Einhorn D, Rendell MS, Rosenzweig J et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000, 22: 1395-1409.
37. Kipnes MS, Krosnick A, Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001, 111: 10-17.
38. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992, 15: 318-368.
39. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependant NIDDM. Genetic and clinical implications. Diabetes 1995, 44: 863-870.
40. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999, 42: 128-138.
41. Girard J. Acide gras et cellule β. Diabetes Metab 2000, 26: 6-9.
42. Girard J. Cellule β-pancréatique, glitazones et diabète de type 2. Masson Thérapeutique-Diabétologie 2003, ACB/018 (8 pages).
43. Verges B. Antidiabétiques oraux et lipides. Ann Endocrinoi 2002, 63, 1S45-1S50.
44. Verges B. Dyslipidémies et diabète de type 2. Masson Thérapeutique-Diabétologie 2003, ACB/014 (5 pages).
45. Hanefeld M, Göke B. Combining pioglitazone with a sulfonylurea or metformin in the management of type 2 diabetes. Exp Clin Endocrinol Diabetes 2000, 108 (Suppl.2): S256-S266.
46. Winkler K, Friedrich I, Baumstark MW, Wieland H, März W. Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus. Br J Diabetes Vasc Dis 2002, 2: 143-148.
47. Winkler K, Konrad T, Füllert S et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension. Diabetes Care 2003, 26: 2588-2594.
48. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JPD. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004, 27: 41-46.
49. Suraamornkul S, Glass L, Kashyap R et al. Effects of pioglitazone versus fenofibrate treatment on glucose and fat metabolism in patients with type 2 diabetes. Diabetologia 2003, 46 (Suppl.2): A289 [Abstract PS833].
50. Moules I, Maher U, Edwards GC et al. A comparison of the effects of pioglitazone and gliclazide on metabolic control in drug-naïve patients with Type 2 diabetes. Diabetes Metab 2003, 29 (Hors série 2): 4S252 [Abstract 2296].
51. Robinson P, Lee CEF, Edwards GC, Urquhart R, Tan MH. A comparison of the effect of pioglitazone and gliclazide monotherapy on lipid profiles in drug-naïve patients with Type 2 diabetes. Diabetologia 2003, 46 (Suppl.2): A291 [Abstract PS839].
52. Lenton S, Schernthaner G, Edwards G, Lee C, Tan M, Herz M. The efficacy of pioglitazone compared to metformine in drug-naive patients with Type 2 diabetes. Diabetologia 2003, 46 (Suppl.2): A286 [Abstract PS828].
53. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH on behalf of the QUARTET Study Group. One-year gly-1 cemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004, 27: 141-147.
54. Lambert C, Belcher G, Edwards G et al. Weight changes with treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Diabetes Metab 2003, 29 (Hors série 2): 4S150 [Abstract 1885].
55. Maher LJ, Edwards GC, Lee CEF, Urquhart R, Herz M, Tan MH. Long-term combination therapy with pioglitazone plus metformin for type 2 diabetes: a randomised, comparative study with gliclazide plus metformin. Diabetologia 2003, 46 (Suppl.2): A288 [Abstract PS831].
56. Girard J. Effet antidiabétique des thiazolidinediones In « Journée de Diabétologie. Hôtel-Dieu 2001 ». Flammarion. Medecine-Sciences. Paris. 2001. pp 33-45.
57. (y), ob/ob, and db/db mice. Diabetes 2003, 52 (Suppl.1): A116 [Abstract 499-P].
58. Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic woman. Diabetes 2002, 51: 2796-2803.
59. Xiang AH, Peters RK, Kjos SL et al. Continued protection from diabetes during treatment of the TRIPOD cohort with pioglitazone, Diabetes 2003,52 (Suppl.1): A75 [Abstract 322-OR].
60. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004, 47: 31-39.
61. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes. Diabetes 1995, 44: 1249-125.
62. Duez H, Fruchart JC, Staels B. PPARs in inflammation, atherosclerosis and thrombosis. J Cardiovasc Risk 2001, 8: 187-194.
63. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001, 134: 61-71.
64. Glass CK. Antiatherogenic effects of thiazolidinediones [Editorial]. Arterioscl Thromb Vasc Biol 2001, 21: 295-296.
65. Lebovitz HE. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus. Am J Cardiol 2002, 90 (Suppl.): 34G-41G.
66. Aroda VR, Henry RR. Thiazolidinediones: potential link between insulin resistance and cardiovascular disease. Diabetes Spectrum 2003, 16: 120-125.
67. Kotchen TA, Reddy S, Zhang HY. Increasing insulin sensitivity lowers blood pressure in the fructose-fed rat. Am J Hypertens 1997, 10: 1020-1026.
68. Satoh H, Tsukamoto K, Hashimoto Y et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARγ on vascular endothelial function. Biochem Biophys Res Commun 1999, 254: 757-763.
69. Kato K, Satoh H, Endo Y et al. Thiazolidinediones down-regulate plasminogen-activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARγ in endothelial function. Biochem Biophys Res Commun 1999, 254: 431-435.
70. Gralinski MR, Rowse PE, Breider MA. Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro. J Cardiovasc Pharmacol 1998, 31: 909-913.
71. Game BA, Maldonado A, Huang Y. Pioglitazone inhibits oxidized LDL-stimulated matrix metalloproteinase-1 expression in human vascular smooth muscle cells through a mitogen-activated protein kinase-independent mechanism. Diabetes 2003, 52 (Suppl.1): A20 [Abstract 85-OR].
72. Harry P, Urquhart R, Lee CE et al. The effects of pioglitazone, metformin or gliclazide therapy on urinary albumin: creatinine ratio. Modification of a cardiovascular risk marker. Diabetes Metab 2003, 29 (Hors série 2): 4S251 [Abstract 2294].
73. World Health Organisation. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Department of Non Communicable Disease Surveillance. Technical report NCS/99-2. W.H.O. Geneva, Switzerland. 1999.
74. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24: 683-689.
75. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997, 157: 1413-1418.
76. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 1999, 42: 263-285.
77. Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complic 2000, 14: 250-254.
78. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001, 50: 1193-1196.
79. Satoh N, Ogawa Y, Usui T et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003, 26: 2493-2499.
80. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001, 86: 3452-3456.
81. Charbonnel B, Lenton S. L'étude PROactive: description et caractéristique des patients. Diabetes Metab 2003, 29 (Hors série 1): 1S58 [Abstract P78].